Corrigendum to “A systematic review of higher-risk myelodysplastic syndromes clinical trials to determine the benchmark of azacitidine and explore alternative endpoints for overall survival” (Leukemia Research (2021) 104, (S0145212621000564), (10.1016/j.leukres.2021.106555))

Jacqueline S. Garcia, Ronan T. Swords, Gail J. Roboz, Meagan A. Jacoby, Guillermo Garcia-Manero, Wan Jen Hong, Xiaoqing Yang, Ying Zhou, Uwe Platzbecker, David P. Steensma, Johannes E. Wolff, Pierre Fenaux

Research output: Contribution to journal › Comment/debate › peer-review

Fingerprint

Dive into the research topics of 'Corrigendum to “A systematic review of higher-risk myelodysplastic syndromes clinical trials to determine the benchmark of azacitidine and explore alternative endpoints for overall survival” (Leukemia Research (2021) 104, (S0145212621000564), (10.1016/j.leukres.2021.106555))'. Together they form a unique fingerprint.

Medicine & Life Sciences